Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone

Lung Cancer

Volumn 40, Issue 3, 2003, Pages 317-323

  Jeremic, Branislav ^a,c   Shibamoto, Yuta ^b   Milicic, Biljana ^a   Dagovic, Aleksandar ^a   Nikolic, Nebojsa ^a   Aleksandrovic, Jasna ^a   Acimovic, Ljubisa ^a   Milisavljevic, Slobodan ^a  

^a University Hospital

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Early stage; Hyperfractionation; Non small cell lung cancer; Toxicity; Treatment interruption

Indexed keywords

ADULT; ARTICLE; BONE DISEASE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS; FEMALE; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; RADIATION SICKNESS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

EID: 0038359752     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00078-3     Document Type: Article

References (31)

1. Mountain C.F. A new international staging system for lung cancer. Chest. 89:(Suppl.):1986;225S-233S.
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
3. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiov. Surg. 96:1998;440-447.
4. Haffty B.G., Goldberg N.B., Gerstley J., Fischer D.B., Peschel R.E. Results of radical radiation therapy in clinical Stage I, technically operable non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 15:1988;69-73.
5. Talton B.M., Constable W.C., Kersh C.R. Curative radiotherapy for technically operable stage I nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;15-21.
6. Rosenthal S.A., Curran W.J. Jr., Herbert S.H., et al. Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease). Cancer. 70:1992;3410-3417.
7. Dosoretz D.E., Katin M.J., Blitzer P.H., et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int. J. Radiat. Oncol. Biol. Phys. 25:1992;3-9.
8. Kaskowitz L., Graham M.V., Emami B., Halverson K.J., Rush C. Radiation therapy alone for stage I non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 27:1993;517-523.
9. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;521-525.
10. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiotherapy for clinical stage II nonsmall cell lung cancer. Radiother. Oncol. 51:1999;141-145.
11. Suit H.D. Potential for improving survival rates for the cancer patient by increasing the efficacy of treatment of the primary lesion. Cancer. 50:1982;1227-1234.
12. Suit H.D., Westgate S.J. Impact of improved local control on survival. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;453-458.
13. Suit H.D. The scope of the problem of primary tumor control. Cancer. 61:1988;2141-2147.
14. Suit H.D. Local control and patient survival. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;653-660.
15. Overgaard M., Hjem-Hansen M., Vandelbo J.L., Anderson A.P. Comparison of conventional and split course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol. 27:1988;147-161.
16. Pajak T.F., Laramore G.E., Marcial V.A., et al. Elapsed treatment days: a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int. J. Radiat. Oncol. Biol. Phys. 20:1991;13-20.
17. Fowler J.F., Lindstrom M.J. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;457-467.
18. Cox J.D., Pajak T.F., Marcial V.A., et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the respiratory/digestive tracts: new evidence for accelerated proliferation from RTOG Protocol 83-13. Cancer. 69:1992;2744-2748.
19. Cox J.D., Pajak T.F., Asbell S., et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 radiation therapy oncology group (RTOG) trials. Int. J. Radiat. Oncol. Biol. Phys. 27:1993;493-498.
20. Koukourakis M., Hlouverakis G., Kosma L., et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;315-322.
21. Chen M., Jiang G.-L., Fu X.-L., et al. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer. Lung Cancer. 28:2000;11-19.
22. Willers H., Wurschmidt F., Bunemann H., Heilmann H.-P. High-dose radiation therapy alone for inoperable non-small cell lung cancer. Acta Oncol. 37:1998;101-105.
23. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 31:1995;1341-1346.
24. Maciejewski B., Preuss-Beyer G., Trott K.R. Influence of number of fractions and overall treatment time on the local tumour control of cancer of the larynx. Int. J. Radiat. Oncol. Biol. Phys. 9:1983;321-328.
25. Taylor J.M.G., Withers H.R., Mendenhall W.M. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother. Oncol. 17:1989;95-102.
26. Ball D., Bishop J., Smith J., et al. A randomized phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother. Oncol. 52:1999;129-136.
27. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M.(on behalf of the CHART steering committee), Radiother Oncol 52: 1999; 137-148.
28. Bentzen S.M., Saunders M.I., Dische S., Parmar M.K. Updated data for CHART in NSCLC: further analyses. Radiother. Oncol. 55:2000;86-87.
29. Noordijk E.M., vd-Poest-Clement E., Hermans J., Wever A.M., Leer J.W. Radiotherapy as an alternative to surgery in elderly patients 8th respectable lung cancer. Radiother. Oncol. 13:1988;83-89.
30. Krol A.D.G., Aussems P., Noordijk E.M., Hermans J., Leer J.W.H. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Int. J. Radiat. Oncol. Biol. Phys. 34:1996;297-302.
31. Cheung P.C., Mackillop W.J., Dixon P., Brundage M.D., Youssef Y.M., Zhou S. Involved-field radiotherapy alonje for early-stage non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;703-710.